WO2018212358A1 - 脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物 - Google Patents
脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物 Download PDFInfo
- Publication number
- WO2018212358A1 WO2018212358A1 PCT/JP2018/019469 JP2018019469W WO2018212358A1 WO 2018212358 A1 WO2018212358 A1 WO 2018212358A1 JP 2018019469 W JP2018019469 W JP 2018019469W WO 2018212358 A1 WO2018212358 A1 WO 2018212358A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- peptide vaccine
- vaccine composition
- amino acid
- vegfr
- Prior art date
Links
- 229940023041 peptide vaccine Drugs 0.000 title claims abstract description 162
- 208000019736 Cranial nerve disease Diseases 0.000 title claims abstract description 23
- 208000014826 cranial nerve neuropathy Diseases 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 title claims description 125
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 97
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 70
- 210000004027 cell Anatomy 0.000 claims abstract description 65
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims abstract description 42
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims abstract description 42
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims abstract description 10
- 150000001413 amino acids Chemical class 0.000 claims description 65
- 102000011786 HLA-A Antigens Human genes 0.000 claims description 46
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 46
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 41
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims description 39
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 39
- 208000002761 neurofibromatosis 2 Diseases 0.000 claims description 18
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 abstract description 9
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 abstract description 9
- 230000001939 inductive effect Effects 0.000 abstract 2
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 52
- 208000004064 acoustic neuroma Diseases 0.000 description 52
- 208000014070 Vestibular schwannoma Diseases 0.000 description 36
- 210000004369 blood Anatomy 0.000 description 31
- 239000008280 blood Substances 0.000 description 31
- 206010027191 meningioma Diseases 0.000 description 31
- 229940024606 amino acid Drugs 0.000 description 22
- 238000012360 testing method Methods 0.000 description 18
- 229960005486 vaccine Drugs 0.000 description 17
- 230000002601 intratumoral effect Effects 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 238000003384 imaging method Methods 0.000 description 13
- 208000007538 neurilemmoma Diseases 0.000 description 13
- 230000003247 decreasing effect Effects 0.000 description 12
- 201000009489 neurilemmoma of the fifth cranial nerve Diseases 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- 208000024171 trigeminal schwannoma Diseases 0.000 description 12
- 239000002671 adjuvant Substances 0.000 description 10
- 230000002146 bilateral effect Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 238000012744 immunostaining Methods 0.000 description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 7
- 238000010191 image analysis Methods 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 206010039667 schwannoma Diseases 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 210000003625 skull Anatomy 0.000 description 5
- 210000000278 spinal cord Anatomy 0.000 description 5
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 4
- 206010011878 Deafness Diseases 0.000 description 4
- 206010014967 Ependymoma Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 230000006229 amino acid addition Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 description 4
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 3
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000003792 cranial nerve Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 238000012074 hearing test Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 210000003668 pericyte Anatomy 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000001032 spinal nerve Anatomy 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 241000272186 Falco columbarius Species 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010048865 Hypoacusis Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012155 injection solvent Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- -1 liquid paraffin Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000024523 vestibulocochlear nerve neoplasm Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Definitions
- the present invention relates to peptide vaccines and peptide vaccine compositions for cranial nerve diseases.
- Neuroencephalopathy includes neurofibromatosis type II (NF2), brain tumor, cerebrovascular disease, autoimmune disease, ophthalmic disease and the like.
- NF2 is an autosomal dominant hereditary disease that develops due to a genetic abnormality of the tumor suppressor merlin present in chromosome 22 long arm 22q12.
- the diagnosis of NF2 is confirmed by using as an index the occurrence of an acoustic nerve tumor (exactly a vestibular schwannoma) on both the left and right sides.
- schwannoma occurs in the cranial nerve, spinal nerve, and peripheral nerve, and meningioma, ependymoma, glioma, etc.
- Vascular Endothelial Growth Factor Receptor is a kind of receptor-type tyrosine kinase, and is known to be involved in expression of action of VEGF as a ligand.
- VEGFR-1 In addition to three types of VEGFR, VEGFR-1, VEGFR-2, and VEGFR-3, sVEGFR-1, sVEGFR-2, and sVEGFR-3 are known as soluble VEGFR (soluble VEGFR). Of these, VEGFR-1 and VEGFR-2 are known to be expressed in vascular endothelial cells and play a central role in angiogenesis.
- Patent No. 4931154 Japanese Patent No. 3971769
- an object of the present invention is to provide a peptide vaccine and a peptide vaccine composition that can effectively treat cranial nerve diseases.
- a peptide vaccine for cranial nerve disease comprising a peptide that induces cytotoxic T cells (CTL) against VEGFR-1 expressing cells or a peptide that induces CTL against VEGFR-2 expressing cells.
- CTL cytotoxic T cells
- VEGFR-1-expressing cells a peptide that induces CTL against VEGFR-2 expressing cells.
- the peptide vaccine according to [1], wherein the peptide that induces CTL against VEGFR-1-expressing cells is HLA-A * 24: 02-binding.
- the peptide that induces CTL against a VEGFR-1-expressing cell has the amino acid sequence set forth in SEQ ID NO: 1, or one or more amino acids in the amino acid sequence set forth in SEQ ID NO: 1 deleted, substituted or added
- the peptide vaccine according to [1], wherein the peptide that induces CTL against VEGFR-1-expressing cells is HLA-A * 02: 01-binding.
- the peptide that induces CTL against VEGFR-1-expressing cells is one or more in the amino acid sequence of any one of SEQ ID NOs: 2 to 4 or the amino acid sequence of any of SEQ ID NOs: 2 to 4.
- the peptide vaccine according to [1], wherein the peptide that induces CTL against VEGFR-2 expressing cells is HLA-A * 24: 02 binding.
- the peptide that induces CTL against VEGFR-2 expressing cells is one or more in the amino acid sequence of any one of SEQ ID NOs: 5 to 10 or the amino acid sequence of any of SEQ ID NOs: 5 to 10.
- the peptide vaccine according to [1], wherein the peptide that induces CTL against VEGFR-2 expressing cells is HLA-A * 02: 01-binding.
- the peptide that induces CTL against VEGFR-2 expressing cells is one or more in the amino acid sequence of any one of SEQ ID NOs: 11 to 16 or the amino acid sequence of any of SEQ ID NOs: 11 to 16.
- a peptide vaccine and a peptide vaccine composition that can effectively treat cranial nerve diseases can be provided.
- FIG. 1 A) to (e) are photographs showing the results of imaging meningioma of the patient of case 1 by head contrast MRI examination in Experimental Example 2.
- FIG. 2 it is a graph which shows the result of having measured the volume of the meningioma on each test day based on the result of the head contrast MRI test
- FIG. 2 A) to (e) are photographs showing the results of imaging the right and left vestibular schwannomas of the patient of Case 1 by head contrast MRI examination in Experimental Example 2.
- (A) is a graph which shows the result of having measured the volume of the right vestibular schwannoma in each examination day based on the result of the head contrast MRI examination in example 2 of an experiment.
- (B) is a graph which shows the result of having measured the volume of the left vestibular schwannoma on each examination day based on the head contrast MRI examination result in Experimental example 2.
- (A) to (f) are photographs showing the results of imaging the trigeminal schwannomas of the patient in case 2 by head-enhanced MRI examination in experimental example 3.
- it is a graph which shows the result of having measured the volume of the trigeminal schwannoma in each test day based on the result of the head contrast MRI test.
- (A) to (f) are photographs showing the results of photographing the right and left vestibular schwannomas of the patient of Case 2 by head contrast MRI examination in Experimental Example 3.
- (A) is a graph which shows the result of having measured the volume of the right vestibular schwannoma on each examination day based on the result of the head contrast MRI examination in example 3 of an experiment.
- (B) is a graph which shows the result of having measured the volume of the left vestibular schwannoma on each examination day based on the head contrast MRI examination result in Experimental example 3.
- Experimental example 2 it is a graph which shows the result of having measured the blood volume in the tumor of meningioma.
- (A) is a graph which shows the result of having measured the blood volume in the tumor of the right vestibular schwannoma in Experimental example 2.
- FIG. (B) is a graph showing the results of measuring the intratumoral blood volume of the left vestibular schwannomas in Experimental Example 2.
- Experimental example 3 it is a graph which shows the result of having measured the blood volume in the tumor of a trigeminal schwannoma.
- A) is a graph which shows the result of having measured the blood volume in the tumor of the right vestibular schwannoma in Experimental example 3.
- FIG. (B) is a graph showing the results of measuring the intratumoral blood volume of the left vestibular schwannomas in Experimental Example 3.
- (A) And (b) is a graph which shows the result of the speech intelligibility test done to the patient of case 2 in Experimental example 3.
- FIG. 1 is a graph which shows the result of having measured the volume of the left vestibular schwannoma in each examination day based on the result of the head contrast MRI examination in example 4 of an experiment.
- (B) is a graph showing the result of measuring the volume of meningioma on each examination day based on the result of the head contrast MRI examination in Experimental Example 4.
- (A) is a graph which shows the result of having measured the intratumoral blood volume of the right vestibular schwannoma in Experimental Example 4.
- (B) is a graph showing the results of measuring the intratumoral blood volume of the left vestibular schwannomas in Experimental Example 4.
- (A)-(d) are photographs showing the results of imaging bilateral vestibular schwannomas of the patient of case 6 by head-enhanced MRI examination in experimental example 5.
- (A) is a graph which shows the result of having measured the volume of the right vestibular schwannoma in each examination day based on the result of the head contrast MRI examination in example 5 of an experiment.
- (B) is a graph which shows the result of having measured the volume of the left vestibular schwannoma on each examination day based on the result of the head contrast MRI examination in Experimental example 5.
- FIG. (A) is the graph which shows the result of having measured the blood volume in the tumor of the right vestibular schwannoma in Experimental example 6.
- FIG. (B) is a graph showing the results of measuring the intratumoral blood volume of the left vestibular schwannomas in Experimental Example 6.
- (A)-(d) are photographs showing the results of imaging meningiomas of the patient of case 6 by head-enhanced MRI examination in experimental example 6.
- it is a graph which shows the result of having measured the volume of the meningioma on each test day based on the result of the head contrast MRI test
- In Experimental example 6 it is a graph which shows the result of having measured the blood volume in the tumor of meningioma.
- FIG. 10 is a graph showing the results of quantitative RT-PCR in Experimental Example 7.
- A is a photomicrograph showing the results of immunostaining before administration of the peptide vaccine composition in Experimental Example 7.
- B is a photomicrograph showing the results of immunostaining after administration of the peptide vaccine composition in Experimental Example 7.
- A is a photomicrograph showing the results of immunostaining before administration of the peptide vaccine composition in Experimental Example 7.
- B) is a photomicrograph showing the results of immunostaining after administration of the peptide vaccine composition in Experimental Example 7. It is a fluorescence micrograph which shows the result of the immuno-staining in Experimental example 7.
- the present invention provides a peptide vaccine against cranial nerve disease, comprising a peptide that induces CTL against VEGFR-1-expressing cells, or a peptide that induces CTL against VEGFR-2 expressing cells.
- the cranial nerve disease includes cranial nerve diseases involved in angiogenesis, and more specifically, tumors, brain tumors, cerebrovascular diseases, autoimmunity occurring in patients with neurofibromatosis type II (NF2) Examples include diseases and ophthalmic diseases.
- NF2 neurofibromatosis type II
- tumors that occur in NF2 patients include schwannomas, meningiomas, ependymomas, and gliomas.
- schwannomas include schwannomas that occur in cranial nerves, spinal nerves, and peripheral nerves, and more specifically include vestibular schwannomas and trigeminal schwannomas.
- Meningiomas, ependymomas, and gliomas include tumors that occur in the skull and tumors that occur in the spinal cord.
- Brain tumors include glioma, meningioma, schwannoma, pituitary adenoma, craniopharyngioma, chordoma, ependymoma, hemangioblastoma, hemangioperiosteum, metastatic brain tumor, medulloblastoma, malignant Examples include lymphoma.
- cerebrovascular diseases include cerebrovascular malformations and hereditary telangiectasia.
- the autoimmune disease include optic neuromyelitis and giant cell arteritis.
- ophthalmic diseases include age-related macular degeneration and diabetic retinopathy.
- a cranial nerve disease can be effectively treated by administering the peptide vaccine of the present embodiment to a cranial nerve disease patient.
- Human VEGFR-1 is a cell membrane protein consisting of 1338 amino acids. Human VEGFR-1 is a vascular endothelial growth factor receptor essential for neovascular growth and is highly expressed in tumor neovascular endothelial cells of solid tumors. Human VEGFR-2 is a cell membrane protein consisting of 1356 amino acids. Human VEGFR-2 is highly expressed in neoplastic vascular endothelial cells of solid tumors and is involved in the proliferation and migration of vascular endothelial cells.
- the peptide vaccine of this embodiment can induce CTLs against VEGFR-1 expressing cells or VEGFR-2 expressing cells.
- CTL induced in the patient's body by administration of the peptide vaccine of this embodiment is considered to cause tumor growth suppression by specifically destroying the blood vessels of tumors that occur in cranial nerve diseases. Furthermore, since a part of CTL persists as memory T cells, it is considered that a long-term therapeutic effect is exhibited even after completion of administration of the peptide vaccine.
- effectively treating a tumor may be, for example, suppressing an increase in tumor volume or decreasing a tumor volume.
- peptides can be used as peptides that induce CTLs against VEGFR-1-expressing cells and peptides that induce CTLs against VEGFR-2 expressing cells. Some known peptides have been confirmed to be safe when administered to humans in clinical trials. Such peptides are easy to apply clinically because some clinical trials can be omitted.
- the length of the peptide may be less than about 40 amino acids, less than about 20 amino acids, or less than about 15 amino acids.
- the length of the peptide may be 8-11 amino acids, 9 amino acids, or 10 amino acids.
- the peptide in the peptide vaccine of this embodiment, can be prepared by a known method.
- peptides may be prepared by recombinant DNA techniques or by chemical synthesis.
- the peptide may have various modifications as long as it has an activity to induce CTL.
- a sugar chain, a fatty acid, a polyalkylene glycol chain, or the like may be bound to the peptide.
- the peptide may contain D-form amino acids.
- the side chain of the peptide may be modified such as oxidation or phosphorylation.
- the peptide may form a salt such as trifluoroacetate, acetate or hydrochloride.
- human leukocyte antigen is a membrane protein also called a histocompatibility antigen and plays an important role in the immune mechanism. It is known that there are many types of HLA. In order for a peptide vaccine to function effectively, it is necessary for the peptide to have binding properties to the same type of HLA as the patient's HLA type.
- HLA-A * 24: 02, HLA-A * 02: 01, HLA-A * 02: 06, HLA-A * 02: 07, etc. are relatively frequent especially in Japanese.
- the peptide vaccine of the present embodiment is HLA-A * 24: 02 binding (restricted) or HLA-A * 02: 01 binding, to HLA-A * 02: 06, HLA-A * 02: 07 Can be effectively functioning in many Japanese patients.
- the peptide that induces CTL against VEGFR-1-expressing cells may be HLA-A * 24: 02-binding or HLA-A * 02: 01-binding. Alternatively, it may be HLA-A * 02: 06 binding or HLA-A * 02: 07 binding.
- the peptide that induces CTL against VEGFR-2 expressing cells may be HLA-A * 24: 02 binding, HLA-A * 02: 01 binding, or HLA-A. * 02: 06 binding may be used, and HLA-A * 02: 07 binding may be used.
- HLA-A * 02: 07 binding may be used.
- HLA-A * 24 02-binding peptide that induces CTL against VEGFR-1-expressing cells
- HLA-A * 24: 02 binding peptides that can induce CTL against VEGFR-1-expressing cells are already known.
- An example of such a peptide is a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1.
- the peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1 may have a mutation as long as it can induce CTL against VEGFR-1-expressing cells.
- the peptide that induces CTL against VEGFR-1-expressing cells may be, for example, a peptide consisting of an amino acid sequence in which one or more amino acids are deleted, substituted, or added in the amino acid sequence shown in SEQ ID NO: 1.
- the number of one or more is preferably one, two or three.
- the amino acid substitution include substitution of the second amino acid from the N-terminus with phenylalanine, tyrosine, methionine or tryptophan, and substitution of the C-terminal amino acid with phenylalanine, leucine, isoleucine, tryptophan or methionine.
- amino acid addition include addition of 1 to 2 amino acids at the N-terminal or C-terminal.
- HLA-A * 02 01-binding peptide that induces CTL against VEGFR-1-expressing cells
- HLA-A * 02: 01 binding peptides that can induce CTL against VEGFR-1-expressing cells are already known.
- Examples of such peptides include peptides consisting of the amino acid sequences set forth in SEQ ID NOs: 2 to 4.
- the peptide consisting of the amino acid sequence set forth in any of SEQ ID NOs: 2 to 4 may have a mutation as long as it can induce CTLs against VEGFR-1-expressing cells.
- the peptide that induces CTL against VEGFR-1-expressing cells is, for example, a peptide consisting of an amino acid sequence in which one or more amino acids are deleted, substituted, or added in the amino acid sequence shown in any of SEQ ID NOs: 2 to 4. There may be.
- the number of one or more is preferably one, two or three.
- amino acid substitution include substitution of the second amino acid from the N-terminus with leucine or methionine, and substitution of the C-terminal amino acid with valine or leucine.
- amino acid addition include addition of 1 to 2 amino acids at the N-terminal or C-terminal.
- HLA-A * 24 02-binding peptide that induces CTL against VEGFR-2 expressing cells
- HLA-A * 24: 02 binding peptides that can induce CTL against VEGFR-2 expressing cells are already known.
- Examples of such a peptide include a peptide consisting of the amino acid sequence set forth in any of SEQ ID NOs: 5 to 10.
- the peptide consisting of the amino acid sequence described in any of SEQ ID NOs: 5 to 10 may have a mutation as long as it can induce CTLs against VEGFR-2 expressing cells.
- a peptide that induces CTL against a VEGFR-2 expressing cell is, for example, a peptide consisting of an amino acid sequence in which one or more amino acids are deleted, substituted, or added in the amino acid sequence shown in any of SEQ ID NOs: 5 to 10. There may be.
- the number of one or more is preferably one, two or three.
- the amino acid substitution include substitution of the second amino acid from the N-terminus with phenylalanine, tyrosine, methionine or tryptophan, and substitution of the C-terminal amino acid with phenylalanine, leucine, isoleucine, tryptophan or methionine.
- amino acid addition include addition of 1 to 2 amino acids at the N-terminal or C-terminal.
- HLA-A * 02 01-binding peptide that induces CTL against VEGFR-2 expressing cells
- HLA-A * 02: 01 binding peptides that can induce CTL against VEGFR-2 expressing cells are already known.
- Examples of such a peptide include a peptide consisting of the amino acid sequence set forth in any of SEQ ID NOs: 11 to 16.
- the peptide consisting of the amino acid sequence set forth in any of SEQ ID NOs: 11 to 16 may have a mutation as long as it can induce CTLs against VEGFR-2 expressing cells.
- the peptide that induces CTL against VEGFR-2 expressing cells is, for example, a peptide consisting of an amino acid sequence in which one or more amino acids are deleted, substituted, or added in the amino acid sequence shown in any of SEQ ID NOs: 11 to 16. There may be.
- the number of one or more is preferably one, two or three.
- amino acid substitution include substitution of the second amino acid from the N-terminus with leucine or methionine, and substitution of the C-terminal amino acid with valine or leucine.
- amino acid addition include addition of 1 to 2 amino acids at the N-terminal or C-terminal.
- a peptide consisting of an amino acid sequence (SEQ ID NO: 16) in which the second amino acid from the N-terminus is substituted with leucine is a suitable example.
- CTL induced by stimulation with a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 16 recognizes the peptide before mutation (SEQ ID NO: 12) and can be damaged.
- the present invention provides a peptide vaccine composition for cranial nerve disease comprising the peptide vaccine described above and a pharmaceutically acceptable carrier.
- the peptide vaccine described above may be directly administered to a patient, or may be administered to a patient in the form of the peptide vaccine composition of the present embodiment.
- the inventors have clarified that cranial nerve diseases can be effectively treated by administering the peptide vaccine composition of the present embodiment to cranial nerve disease patients.
- the peptide vaccine composition of this embodiment may contain only one or both of a peptide that induces CTL against VEGFR-1 expressing cells and a peptide that induces CTL against VEGFR-2 expressing cells. You may do it.
- the peptide vaccine composition of the present embodiment can be mixed with a pharmaceutically acceptable carrier and formulated by a general pharmaceutical technique.
- a pharmaceutically acceptable carrier for example, it may be formulated and administered orally in the form of tablets, capsules, elixirs, microcapsules, etc., and parenterally administered in the form of injections, suppositories, external skin preparations, etc. May be.
- the external preparation for skin include dosage forms such as ointments and patches.
- the pharmaceutically acceptable carrier examples include adjuvants, injection solvents, excipients, and adhesives.
- adjuvant those generally used as adjuvants for vaccine preparations can be used without particular limitation, such as sodium hydroxide, aluminum hydroxide, calcium phosphate, aluminum phosphate, alum, pepes, carboxyvinyl polymer, etc.
- oil-based adjuvants such as sedimentary adjuvants, liquid paraffin, lanolin, incomplete Freund's adjuvant, and complete Freund's adjuvant.
- the solvent for injection examples thereof include physiological saline, glucose, D-sorbitol, D-mannose, D-mannitol, sodium chloride and the like. Examples include, but are not limited to, isotonic solutions containing adjuvants.
- the solvent for injection may contain an alcohol such as ethanol; a polyalcohol such as propylene glycol or polyethylene glycol; a nonionic surfactant such as polysorbate 80 (trademark) or HCO-50.
- those used in general preparations can be used without particular limitation, and examples thereof include, but are not limited to, starch and crystalline cellulose.
- pressure-sensitive adhesive those used for general patches can be used without particular limitation, and examples thereof include, but are not limited to, rubber-based pressure-sensitive adhesives and silicone-based pressure-sensitive adhesives.
- the peptide vaccine composition of the present embodiment may be administered together with an active ingredient such as another anticancer agent, or may contain an active ingredient such as another anticancer agent.
- Administration of the peptide vaccine described above or the peptide vaccine composition of this embodiment to a patient can be performed, for example, by oral administration, intradermal administration, subcutaneous administration, intravenous injection, or the like, and may be systemic administration. May be administered locally in the vicinity of the tumor.
- the dose can be appropriately adjusted depending on the patient's age, weight, symptoms, administration method, and the like. Usually, for an adult (body weight 60 kg), for example, 0.001 mg to 1000 mg, eg 0.001 mg to An amount to administer an active ingredient (peptide) of 1000 mg, for example, 0.1 mg to 10 mg can be mentioned.
- the number of times the peptide vaccine or peptide vaccine composition is administered to the patient may be one, but it is preferable to administer the peptide vaccine multiple times in order to efficiently induce CTL.
- the administration interval in the case of multiple administrations may be several days to several months, for example.
- the invention comprises administering to a patient in need of treatment an effective amount of a peptide that induces CTL against a VEGFR-1 expressing cell, or a peptide that induces CTL against a VEGFR-2 expressing cell.
- a method for treating cranial nerve disease is provided.
- the present invention provides a peptide that induces CTL against VEGFR-1 expressing cells or a peptide that induces CTL against VEGFR-2 expressing cells for the treatment of cranial nerve diseases.
- the present invention provides the use of a peptide that induces CTL against a VEGFR-1 expressing cell or a peptide that induces CTL against a VEGFR-2 expressing cell for the manufacture of a therapeutic agent for cranial nerve disease.
- examples of the peptide that induces CTL against VEGFR-1 expressing cells and the peptide that induces CTL against VEGFR-2 expressing cells include those described above.
- the form of the composition containing a pharmaceutically acceptable carrier may be sufficient as said peptide.
- examples of the pharmaceutically acceptable carrier include those described above.
- Case 1 was a 30 year old male.
- the HLA type of the patient of case 1 was HLA-A * 24: 02.
- Bilateral vestibular schwannoma, trigeminal schwannoma, and meningioma occurred in the cranium, and innumerable schwannomas also occurred in the spinal cord and skin. He had no hearing on both sides and was bedridden.
- a total of 4 tumor extractions and 3 ⁇ knife irradiations were performed including intracranial and spinal cord, but it was difficult to control the growth of the tumor, and the tumor was growing year by year.
- the peptide vaccine composition prepared in the same manner as in Experimental Example 1 was administered to the patient of Case 1.
- peptide vaccine composition was subcutaneously administered per time around the patient's bilateral axilla or inguinal lymph node. As an initial administration, it was administered once a week and four times during one month from the start of administration. Thereafter, as a boost administration, it was administered once a month four times. According to the above administration schedule, the peptide vaccine composition was administered a total of 8 times within 5 months from the start of administration.
- FIGS. 1 (a) to 1 (e) show the results after 8 administrations of the peptide vaccine composition.
- arrows indicate meningiomas.
- FIG. 2 is a graph showing the result of measuring the volume of meningioma on each examination day based on the result of the head contrast MRI examination.
- the arrow indicates the start of administration of the vaccine composition.
- FIG. 9 is a graph showing the results of measuring the intratumoral blood volume of meningioma on each examination day based on the results of cephalographic CT examination.
- the arrow indicates the start of administration of the vaccine composition.
- FIGS. 3 (a) to 3 (e) are photographs showing the results of imaging the right and left vestibular schwannomas of the patient of Case 1 by cephalographic MRI examination. At the top of each photo, the shooting date is listed.
- 3 (a) and (b) are the results before administration of the peptide vaccine composition
- FIG. 3 (c) is the result at the start of administration of the peptide vaccine composition
- FIG. 3 (d) is the peptide vaccine composition.
- Fig. 3 (e) shows the result after 8 administrations of the peptide vaccine composition.
- the arrows indicate vestibular schwannomas.
- FIG. 4 (a) is a graph showing the result of measuring the volume of the right vestibular schwannoma on each examination day based on the result of the head-enhanced MRI examination
- FIG. It is a graph which shows the result of having measured the volume of the left vestibular schwannoma on each examination day based on the contrast MRI examination result.
- the arrows indicate the start of administration of the vaccine composition.
- FIG. 10A is a graph showing the results of measuring the intratumoral blood volume of the right vestibular schwannoma on each examination day based on the results of the cephalogram CT examination
- FIG. It is a graph which shows the result of having measured the intratumoral blood volume of the left vestibular schwannoma on each examination day based on the result of the cephalogram CT examination.
- the arrow indicates the start of administration of the vaccine composition.
- Case 2 was a 22 year old female.
- the HLA type of the patient in case 2 was HLA-A * 24: 02.
- Bilateral vestibular schwannomas and trigeminal schwannomas occurred, and numerous schwannomas also occurred in the spinal cord and skin.
- three tumor extraction operations and one ⁇ knife irradiation were performed, but it was difficult to control the growth of the tumor, and the tumor gradually increased.
- the peptide vaccine composition prepared in the same manner as in Experimental Example 1 was administered to the patient of Case 2.
- the administration schedule and image analysis were performed in the same manner as in Experimental Example 2.
- FIGS. 5A to 5F show the effects of administration of the peptide vaccine composition on the patient's tumor.
- 5 (a) to 5 (f) are photographs showing the results of imaging trigeminal schwannomas of NF2 patient in Case 2 by cephalographic MRI examination. At the top of each photo, the shooting date is listed.
- 5 (a) to (c) are the results before administration of the peptide vaccine composition
- FIG. 5 (d) is the result at the start of administration of the peptide vaccine composition
- FIG. 5 (e) is the peptide vaccine composition.
- Fig. 5 (f) shows the results after 8 administrations of the peptide vaccine composition.
- the arrows indicate trigeminal schwannomas.
- FIG. 6 is a graph showing the results of measuring the volume of the trigeminal schwannoma on each examination day based on the results of the head contrast MRI examination.
- the arrow indicates the start of administration of the vaccine composition.
- FIG. 11 is a graph showing the results of measuring the intratumoral blood volume of trigeminal schwannomas on each examination day based on the results of cephalometric CT examination.
- the arrow indicates the start of administration of the vaccine composition.
- FIGS. 7A to 7F are photographs showing the results of imaging the right and left vestibular schwannomas of the patient in Case 2 by cephalographic MRI examination. At the top of each photo, the shooting date is listed. 7 (a) to (c) are the results before administration of the peptide vaccine composition, FIG. 7 (d) is the result at the start of administration of the peptide vaccine composition, and FIG. 7 (e) is the peptide vaccine composition. Fig. 7 (f) shows the results after 8 administrations of the peptide vaccine composition. In FIGS. 7A to 7F, arrows indicate vestibular schwannomas.
- FIG. 8A is a graph showing the result of measuring the volume of the right vestibular schwannoma on each examination day based on the result of the head-enhanced MRI examination
- FIG. It is a graph which shows the result of having measured the volume of the left vestibular schwannoma on each examination day based on the contrast MRI examination result.
- the arrow indicates the start of administration of the vaccine composition.
- the volume of the right vestibular schwannoma which had been on an increasing trend after the start of the administration of the peptide vaccine composition, decreased by about 7% compared to the start of the administration of the peptide vaccine composition.
- Vestibular schwannoma growth was found to have stopped.
- FIG. 12 (a) is a graph showing the results of measuring the intratumoral blood volume of the right vestibular schwannoma on each examination day based on the results of the cephalographic CT examination
- FIG. It is a graph which shows the result of having measured the intratumoral blood volume of the left vestibular schwannoma on each examination day based on the result of the cephalogram CT examination.
- the arrow indicates the start of administration of the vaccine composition.
- FIGS. 13A and 13B are graphs showing the results of the speech intelligibility test performed on the patient of case 2.
- the speech intelligibility test is a test in which a subject is made to listen to a voice to measure how much the word can be understood and how much the volume is increased to make the voice easier to understand.
- FIG. 13 (a) shows the test results before the start of administration of the peptide vaccine composition
- FIG. 13 (b) shows the test results after four administrations of the peptide vaccine composition.
- the result of the speech intelligibility test was 60% at 70 dB before the start of the administration of the peptide vaccine composition, but it became possible to discriminate about 70% at 70 dB after the administration of the peptide vaccine composition four times, thereby improving hearing. was recognized.
- Case 5 was a 41 year old female.
- the HLA type of the patient in case 5 was HLA-A * 24: 02.
- the right auditory schwannoma was operated at age 23. He was also re-operated at the age of 26.
- MRI showed an increase in bilateral auditory schwannomas and meningiomas on the back of the left pyramidal bone.
- Administration of the peptide vaccine composition prepared in the same manner as in Experimental Example 1 was started.
- the administration schedule and image analysis were performed in the same manner as in Experimental Example 2.
- FIG. 14 (a) to (d) are the results before administration of the peptide vaccine composition
- FIG. 14 (e) is the result after four administrations of the peptide vaccine composition
- FIG. 14 (f) is the peptide vaccine composition. It is the result after administration of the composition 8 times.
- FIG. 15A is a graph showing the result of measuring the volume of the left vestibular schwannoma on each examination day based on the result of the head-enhanced MRI examination
- FIG. It is a graph which shows the result of having measured the volume of the meningioma on each test day based on the result of a contrast MRI test.
- the arrow indicates the start of administration of the vaccine composition.
- the volume of the left vestibular schwannoma which had been increasing until then, decreased by 34%.
- the volume of meningioma which had been increasing until then, decreased by 10%, and thereafter showed a tendency to suppress increase.
- FIG. 16 (a) is a graph showing the results of measuring the intratumoral blood volume of the left vestibular schwannoma on each examination day based on the results of cephalographic CT examination
- FIG. It is a graph which shows the result of having measured the blood volume in the tumor of the meningioma on each test day based on the result of a head contrast CT test.
- the arrow indicates the start of administration of the vaccine composition. As a result, it was revealed that the blood volume in the tumor showed a tendency to decrease after administration of the peptide vaccine composition.
- the pure tone hearing test is a test for measuring the volume of sound with seven different sounds from 125 Hz to 8,000 Hz and examining the volume of the smallest sound that can be heard. As a result, after the administration of the peptide vaccine composition 8 times, a tendency to improve left hearing was observed.
- FIGS. 17A to 17D are photographs showing the results of imaging bilateral vestibular schwannomas of the patient of case 6 by cephalographic MRI examination. At the top of each photo, the shooting date is listed.
- FIG. 17 (a) shows the results before the administration of the peptide vaccine composition
- Fig. 17 (b) shows the results before the start of the administration of the peptide vaccine composition
- Fig. 17 (c) shows the peptide vaccine composition four times.
- FIG. 17 (d) shows the result after 8 administrations of the peptide vaccine composition.
- FIG. 18A is a graph showing a result of measuring the volume of the right vestibular schwannoma on each examination day based on the result of the head-enhanced MRI examination
- FIG. It is a graph which shows the result of having measured the volume of the left vestibular schwannoma on each examination day based on the result of contrast MRI examination.
- the arrow indicates the start of administration of the vaccine composition.
- the volume of the right vestibular schwannoma which had been increasing until then, decreased by 5%.
- the volume of the left vestibular schwannoma which had been increasing until then, decreased by 13%.
- FIG. 19 (a) is a graph showing the results of measuring the intratumoral blood volume of the right vestibular schwannoma on each examination day based on the results of cephalographic CT examination
- FIG. It is a graph which shows the result of having measured the intratumoral blood volume of the left vestibular schwannoma on each examination day based on the result of the cephalogram CT examination.
- the arrow indicates the start of administration of the vaccine composition. As a result, it was revealed that the intratumoral blood volume of the right vestibular schwannoma tended to decrease after administration of the peptide vaccine composition.
- FIGS. 20A to 20D are photographs showing the results of imaging meningiomas of the patient in case 6 by cephalographic MRI examination. At the top of each photo, the shooting date is listed.
- FIG. 20 (a) and (b) are the results before administration of the peptide vaccine composition
- FIG. 20 (c) is the result after four administrations of the peptide vaccine composition
- FIG. 20 (d) is the peptide vaccine. It is the result after administration of the composition 8 times.
- FIG. 21 is a graph showing the result of measuring the volume of meningioma on each examination day based on the result of the head contrast MRI examination.
- the arrow indicates the start of administration of the vaccine composition.
- FIG. 22 is a graph showing the results of measuring the intratumoral blood volume of meningioma on each examination date based on the results of cephalographic CT examination.
- the arrow indicates the start of administration of the vaccine composition. As a result, it was revealed that the blood volume in the tumor of meningioma showed a tendency to decrease after administration of the peptide vaccine composition.
- HLA-A * 02: 01-binding peptide vaccine was effective for schwannoma and meningioma in HLA-A * 02: 07 patients.
- FIG. 23 is a graph showing the results of quantitative RT-PCR. As a result, it was revealed that the expression levels of VEGF-A, VEGFR-1, and VEGFR-2 were decreased after administration of the peptide vaccine composition.
- CD34 expression indicates the presence of vascular endothelial cells.
- FIG. 24 (a) and 24 (b) are micrographs showing the results of immunostaining. The magnification is 40 times.
- FIG. 24 (a) shows the results before administration of the peptide vaccine composition
- FIG. 24 (b) shows the results after administration of the peptide vaccine composition.
- FOXP3-positive cells are regulatory T cells.
- FIGS. 25 (a) and (b) are micrographs showing the results of immunostaining. The magnification is 40 times.
- FIG. 25 (a) shows the results before administration of the peptide vaccine composition
- FIG. 25 (b) shows the results after administration of the peptide vaccine composition.
- arrows indicate the presence of FOXP3-positive cells.
- FIG. 26 is a fluorescence micrograph showing the results of immunostaining.
- Pre-vaccine indicates a result before administration of the peptide vaccine composition
- Post-vaccine indicates a result after administration of the peptide vaccine composition
- DAPI indicates the result of staining the nucleus with 4 ′, 6-diamidino-2-phenylindole
- Merge indicates the result of synthesizing the image.
- a peptide vaccine and a peptide vaccine composition that can effectively treat cranial nerve diseases can be provided.
Abstract
Description
[1]VEGFR-1発現細胞に対する細胞傷害性T細胞(CTL)を誘導するペプチド、又はVEGFR-2発現細胞に対するCTLを誘導するペプチドからなる、脳神経疾患に対するペプチドワクチン。
[2]VEGFR-1発現細胞に対するCTLを誘導する前記ペプチドが、HLA-A*24:02結合性である、[1]に記載のペプチドワクチン。
[3]VEGFR-1発現細胞に対するCTLを誘導する前記ペプチドが、配列番号1に記載のアミノ酸配列、又は配列番号1に記載のアミノ酸配列において1又は複数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる、[2]に記載のペプチドワクチン。
[4]VEGFR-1発現細胞に対するCTLを誘導する前記ペプチドが、HLA-A*02:01結合性である、[1]に記載のペプチドワクチン。
[5]VEGFR-1発現細胞に対するCTLを誘導する前記ペプチドが、配列番号2~4のいずれかに記載のアミノ酸配列、又は配列番号2~4のいずれかに記載のアミノ酸配列において1又は複数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる、[4]に記載のペプチドワクチン。
[6]VEGFR-1発現細胞に対するCTLを誘導する前記ペプチドが、HLA-A*02:06結合性又はHLA-A*02:07結合性である、[1]に記載のペプチドワクチン。
[7]VEGFR-2発現細胞に対するCTLを誘導する前記ペプチドが、HLA-A*24:02結合性である、[1]に記載のペプチドワクチン。
[8]VEGFR-2発現細胞に対するCTLを誘導する前記ペプチドが、配列番号5~10のいずれかに記載のアミノ酸配列、又は配列番号5~10のいずれかに記載のアミノ酸配列において1又は複数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる、[7]に記載のペプチドワクチン。
[9]VEGFR-2発現細胞に対するCTLを誘導する前記ペプチドが、HLA-A*02:01結合性である、[1]に記載のペプチドワクチン。
[10]VEGFR-2発現細胞に対するCTLを誘導する前記ペプチドが、配列番号11~16のいずれかに記載のアミノ酸配列、又は配列番号11~16のいずれかに記載のアミノ酸配列において1又は複数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる、[9]に記載のペプチドワクチン。
[11]VEGFR-2発現細胞に対するCTLを誘導する前記ペプチドが、HLA-A*02:06結合性又はHLA-A*02:07結合性である、[1]に記載のペプチドワクチン。
[12]前記脳神経疾患が神経線維腫症II型である、[1]~[11]のいずれかに記載のペプチドワクチン。
[13][1]~[12]のいずれかに記載のペプチドワクチンと、薬学的に許容される担体とを含有する、NF2患者に発生する腫瘍に対するペプチドワクチン組成物。
1実施形態において、本発明は、VEGFR-1発現細胞に対するCTLを誘導するペプチド、又はVEGFR-2発現細胞に対するCTLを誘導するペプチドからなる、脳神経疾患に対するペプチドワクチンを提供する。
VEGFR-1発現細胞に対するCTLを誘導することができる、HLA-A*24:02結合性のペプチドはすでに知られている。このようなペプチドとしては、例えば、配列番号1に記載のアミノ酸配列からなるペプチドが挙げられる。
VEGFR-1発現細胞に対するCTLを誘導することができる、HLA-A*02:01結合性のペプチドはすでに知られている。このようなペプチドとしては、例えば、配列番号2~4に記載のアミノ酸配列からなるペプチドが挙げられる。
VEGFR-2発現細胞に対するCTLを誘導することができる、HLA-A*24:02結合性のペプチドはすでに知られている。このようなペプチドとしては、例えば、配列番号5~10のいずれかに記載のアミノ酸配列からなるペプチドが挙げられる。
VEGFR-2発現細胞に対するCTLを誘導することができる、HLA-A*02:01結合性のペプチドはすでに知られている。このようなペプチドとしては、例えば、配列番号11~16のいずれかに記載のアミノ酸配列からなるペプチドが挙げられる。
1実施形態において、本発明は、上述したペプチドワクチンと、薬学的に許容される担体とを含有する、脳神経疾患に対するペプチドワクチン組成物を提供する。
1実施形態において、本発明は、VEGFR-1発現細胞に対するCTLを誘導するペプチド、又はVEGFR-2発現細胞に対するCTLを誘導するペプチドの有効量を、治療を必要とする患者に投与することを含む、脳神経疾患の治療方法を提供する。
(ペプチドワクチン組成物の調製)
配列番号1に記載のアミノ酸配列からなるペプチド2mgと、配列番号5に記載のアミノ酸配列からなるペプチド2mgと、不完全フロイントアジュバント(型式「MONTANIDE ISA51」、SEPPIC社)1mLとを混合してエマルジョン化し、ペプチドワクチン組成物2mLを調製した。
(症例1の患者へのペプチドワクチン組成物の投与)
症例1の患者は、30歳の男性であった。症例1の患者のHLA型はHLA-A*24:02であった。頭蓋内に両側前庭神経鞘腫、三叉神経鞘腫及び髄膜腫を生じており、脊髄や皮膚にも無数に神経鞘腫が生じていた。両側の聴力は既に全くなく、寝たきりの状態であった。頭蓋内や脊髄を含めて、計4回の腫瘍摘出術及び3回のγナイフ照射を行ったが、腫瘍の増大を制御することは困難であり、腫瘍は年々増大していた。症例1の患者に、実験例1と同様にして調製したペプチドワクチン組成物の投与を行った。
患者の両側腋窩又は鼠径リンパ節周囲に、1回あたりペプチドワクチン組成物1mLを皮下投与した。初期投与として、投与開始から1ヶ月の間に、1週間に1回、4回投与した。その後、ブースト投与として、1ヶ月に1回、4回投与した。以上の投与スケジュールにより、投与開始から5か月間で、ペプチドワクチン組成物を合計8回投与した。
頭部造影MRI検査により、ペプチドワクチン組成物の投与が患者の腫瘍に与える影響を検討した。図1(a)~(e)は、頭部造影MRI検査により、症例1の患者の髄膜腫を撮影した結果を示す写真である。各写真の上部には撮影日が記載されている。図1(a)及び(b)はペプチドワクチン組成物の投与前の結果であり、図1(c)はペプチドワクチン組成物の投与開始時の結果であり、図1(d)はペプチドワクチン組成物を4回投与後の結果であり、図1(e)はペプチドワクチン組成物を8回投与後の結果である。図1(a)~(e)中、矢印は髄膜腫を示す。
(症例2の患者へのペプチドワクチン組成物の投与)
症例2の患者は、22歳の女性であった。症例2の患者のHLA型はHLA-A*24:02であった。聴力障害をきっかけにNF2と診断された。両側前庭神経鞘腫、三叉神経鞘腫が生じており、脊髄や皮膚にも多数の神経鞘腫が生じていた。右の聴力は既に無く、左は補聴器をつけて何とか会話ができるレベルであったが、徐々に聴力が低下していた。過去に3回の腫瘍摘出術と、1回のγナイフ照射を行ったが、腫瘍の増大を制御することは困難であり、腫瘍は徐々に増大していた。
頭部造影MRI検査により、ペプチドワクチン組成物の投与が患者の腫瘍に与える影響を検討した。図5(a)~(f)は、頭部造影MRI検査により、症例2のNF2患者の三叉神経鞘腫を撮影した結果を示す写真である。各写真の上部には撮影日が記載されている。図5(a)~(c)はペプチドワクチン組成物の投与前の結果であり、図5(d)はペプチドワクチン組成物の投与開始時の結果であり、図5(e)はペプチドワクチン組成物を4回投与後の結果であり、図5(f)はペプチドワクチン組成物を8回投与後の結果である。図5(a)~(f)中、矢印は三叉神経鞘腫を示す。
(症例5の患者へのペプチドワクチン組成物の投与)
症例5の患者は、41歳の女性であった。症例5の患者のHLA型はHLA-A*24:02であった。23歳で両側聴神経鞘腫を発症し、NF2と診断された。右側聴神経鞘腫は23歳時に手術した。更に26歳時にも再手術した。右の聴力は術後低下し、左の聴力も低下傾向となった。2015年3月のMRIで両側聴神経鞘腫、左錐体骨後面の髄膜腫は増大傾向を示した。実験例1と同様にして調製したペプチドワクチン組成物の投与を開始した。投与スケジュール及び画像解析は実験例2と同様にして行った。
頭部造影MRI検査により、ペプチドワクチン組成物の投与が患者の腫瘍に与える影響を検討した。図14(a)~(f)は、頭部造影MRI検査により、症例5の患者の左側前庭神経鞘腫及び髄膜腫を撮影した結果を示す写真である。各写真の上部には撮影日が記載されている。
(ペプチドワクチン組成物の調製)
配列番号3に記載のアミノ酸配列からなるペプチド2mgと、配列番号16に記載のアミノ酸配列からなるペプチド2mgと、不完全フロイントアジュバント(型式「MONTANIDE ISA51」、SEPPIC社)1mLとを混合してエマルジョン化し、ペプチドワクチン組成物2mLを調製した。
(症例6の患者へのペプチドワクチン組成物の投与)
症例6の患者は、23歳の男性であった。症例6の患者のHLA型はHLA-A*02:07であった。2008年より左耳鳴りを感じていた。また同時に皮膚にも腫瘍が生じたため切除し、NF2と診断された。2011年に両側前庭神経鞘腫が発見された。その後両側聴力は徐々に低下しており、軽度呂律困難も生じ始めている。また前頭蓋底に髄膜腫を認め、その後も急速に増大傾向を示していた。実験例5と同様にして調製したペプチドワクチン組成物の投与を開始した。投与スケジュール及び画像解析は実験例2と同様にして行った。
頭部造影MRI検査により、ペプチドワクチン組成物の投与が患者の腫瘍に与える影響を検討した。図17(a)~(d)は、頭部造影MRI検査により、症例6の患者の両側前庭神経鞘腫を撮影した結果を示す写真である。各写真の上部には撮影日が記載されている。
(組織学的解析)
症例1の患者の、ペプチドワクチン組成物の投与前及び投与後の腫瘍組織におけるVEGF-A、VEGFR-1、VEGFR-2の発現量を定量的RT-PCRにより測定した。
Claims (13)
- Vascular Endothelial Growth Factor Receptor(VEGFR)-1発現細胞に対する細胞傷害性T細胞(CTL)を誘導するペプチド、又はVEGFR-2発現細胞に対するCTLを誘導するペプチドからなる、脳神経疾患に対するペプチドワクチン。
- VEGFR-1発現細胞に対するCTLを誘導する前記ペプチドが、HLA-A*24:02結合性である、請求項1に記載のペプチドワクチン。
- VEGFR-1発現細胞に対するCTLを誘導する前記ペプチドが、配列番号1に記載のアミノ酸配列、又は配列番号1に記載のアミノ酸配列において1又は複数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる、請求項2に記載のペプチドワクチン。
- VEGFR-1発現細胞に対するCTLを誘導する前記ペプチドが、HLA-A*02:01結合性である、請求項1に記載のペプチドワクチン。
- VEGFR-1発現細胞に対するCTLを誘導する前記ペプチドが、配列番号2~4のいずれかに記載のアミノ酸配列、又は配列番号2~4のいずれかに記載のアミノ酸配列において1又は複数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる、請求項4に記載のペプチドワクチン。
- VEGFR-1発現細胞に対するCTLを誘導する前記ペプチドが、HLA-A*02:06結合性又はHLA-A*02:07結合性である、請求項1に記載のペプチドワクチン。
- VEGFR-2発現細胞に対するCTLを誘導する前記ペプチドが、HLA-A*24:02結合性である、請求項1に記載のペプチドワクチン。
- VEGFR-2発現細胞に対するCTLを誘導する前記ペプチドが、配列番号5~10のいずれかに記載のアミノ酸配列、又は配列番号5~10のいずれかに記載のアミノ酸配列において1又は複数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる、請求項7に記載のペプチドワクチン。
- VEGFR-2発現細胞に対するCTLを誘導する前記ペプチドが、HLA-A*02:01結合性である、請求項1に記載のペプチドワクチン。
- VEGFR-2発現細胞に対するCTLを誘導する前記ペプチドが、配列番号11~16のいずれかに記載のアミノ酸配列、又は配列番号11~16のいずれかに記載のアミノ酸配列において1又は複数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる、請求項9に記載のペプチドワクチン。
- VEGFR-2発現細胞に対するCTLを誘導する前記ペプチドが、HLA-A*02:06結合性又はHLA-A*02:07結合性である、請求項1に記載のペプチドワクチン。
- 前記脳神経疾患が神経線維腫症II型である、請求項1~11のいずれか一項に記載のペプチドワクチン。
- 請求項1~12のいずれか一項に記載のペプチドワクチンと、薬学的に許容される担体とを含有する、脳神経疾患に対するペプチドワクチン組成物。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/614,637 US20200147194A1 (en) | 2017-05-19 | 2018-05-21 | Peptide vaccine and peptide vaccine composition for cranial nerve disease |
JP2019518906A JP7168228B2 (ja) | 2017-05-19 | 2018-05-21 | 脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物 |
CN201880030132.5A CN110612115A (zh) | 2017-05-19 | 2018-05-21 | 针对脑神经疾病的肽疫苗和肽疫苗组合物 |
EP18801526.7A EP3626260A4 (en) | 2017-05-19 | 2018-05-21 | PEPTIDIC VACCINE AND PEPTIDIC VACCINE COMPOSITION FOR CRANIAL NERVE DISEASE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017-100361 | 2017-05-19 | ||
JP2017100361 | 2017-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018212358A1 true WO2018212358A1 (ja) | 2018-11-22 |
Family
ID=64273928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/019469 WO2018212358A1 (ja) | 2017-05-19 | 2018-05-21 | 脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20200147194A1 (ja) |
EP (1) | EP3626260A4 (ja) |
JP (1) | JP7168228B2 (ja) |
CN (1) | CN110612115A (ja) |
WO (1) | WO2018212358A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4931154B1 (ja) | 1967-11-22 | 1974-08-19 | ||
WO2004024766A1 (ja) * | 2002-09-12 | 2004-03-25 | Oncotherapy Science, Inc. | Kdrペプチド及びこれを含むワクチン |
JP2010536714A (ja) * | 2007-08-24 | 2010-12-02 | オンコセラピー・サイエンス株式会社 | 抗原ペプチドおよび化学療法薬を用いる膵癌のための併用療法 |
JP2012102105A (ja) * | 2005-02-28 | 2012-05-31 | Oncotherapy Science Ltd | 血管内皮増殖因子受容体1に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン |
JP2017100361A (ja) | 2015-12-02 | 2017-06-08 | セイコーエプソン株式会社 | 液体噴射装置、および、液体噴射装置の製造方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23178A1 (es) * | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
TW201109029A (en) * | 2009-06-11 | 2011-03-16 | Oncotherapy Science Inc | Vaccine therapy for choroidal neovascularization |
US20150359864A1 (en) | 2012-03-09 | 2015-12-17 | Oncotherapy Science, Inc. | Pharmaceutical composition containing peptides |
-
2018
- 2018-05-21 WO PCT/JP2018/019469 patent/WO2018212358A1/ja active Application Filing
- 2018-05-21 CN CN201880030132.5A patent/CN110612115A/zh active Pending
- 2018-05-21 JP JP2019518906A patent/JP7168228B2/ja active Active
- 2018-05-21 US US16/614,637 patent/US20200147194A1/en active Pending
- 2018-05-21 EP EP18801526.7A patent/EP3626260A4/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4931154B1 (ja) | 1967-11-22 | 1974-08-19 | ||
WO2004024766A1 (ja) * | 2002-09-12 | 2004-03-25 | Oncotherapy Science, Inc. | Kdrペプチド及びこれを含むワクチン |
JP3971769B2 (ja) | 2002-09-12 | 2007-09-05 | オンコセラピー・サイエンス株式会社 | Kdrペプチド及びこれを含むワクチン |
JP2012102105A (ja) * | 2005-02-28 | 2012-05-31 | Oncotherapy Science Ltd | 血管内皮増殖因子受容体1に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン |
JP2010536714A (ja) * | 2007-08-24 | 2010-12-02 | オンコセラピー・サイエンス株式会社 | 抗原ペプチドおよび化学療法薬を用いる膵癌のための併用療法 |
JP2017100361A (ja) | 2015-12-02 | 2017-06-08 | セイコーエプソン株式会社 | 液体噴射装置、および、液体噴射装置の製造方法 |
Non-Patent Citations (5)
Title |
---|
See also references of EP3626260A4 |
SIBAO, SHUNSUKE ET AL.: "O-31 VEGFR1/2 vaccinotherapy for malignant glioma", 32TH ACADEMIC CONFERENCE OF THE JAPAN SOCIETY FOR NEURO-ONCOLOGY; PROGRAM AND ABSTRACTS; NOVEMBER 30 - DECEMBER 2, 2014, vol. 32, 2014, JAPAN, pages 141, XP009519176 * |
TODA, MASAHIRO ET AL.: "Abstr. S6-4: Clinical test on VEGFR peptide vaccine for neurofibromatosis type 2", 35TH ACADEMIC CONFERENCE OF THE JAPAN SOCIETY FOR NEURO-ONCOLOGY; PROGRAMS AND ABSTRACTS; NOVEMBER 26-28, 2017, vol. 35, December 2017 (2017-12-01), pages 215, XP009519177 * |
WONG, HK . ET AL.: "Anti-Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related Tumors", CANCER RES., vol. 70, no. 9, 2010, pages 3483 - 3493, XP055549383 * |
YOSHIMURA, K. ET AL.: "Phase l clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma", BRITISH JOURNAL OF CANCER, vol. 108, 2013, pages 1260 - 1266, XP055408106 * |
Also Published As
Publication number | Publication date |
---|---|
EP3626260A1 (en) | 2020-03-25 |
EP3626260A4 (en) | 2021-05-19 |
CN110612115A (zh) | 2019-12-24 |
US20200147194A1 (en) | 2020-05-14 |
JPWO2018212358A1 (ja) | 2020-03-19 |
JP7168228B2 (ja) | 2022-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230338251A1 (en) | Method of treating cancer | |
DE69834494T2 (de) | Vorrichtung zur induktion einer ctl-antwort | |
JP2020196754A (ja) | がん及び感染症の治療方法並びに治療用組成物 | |
JP2019515888A (ja) | 細胞免疫療法前の細胞毒性プレコンディショニングの代替 | |
JP5212849B2 (ja) | 眼内血管新生及び/又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 | |
JP2022543842A (ja) | 植込み型構造体及びその使用 | |
HU228207B1 (hu) | Vakcina és eljárás mozgatóneuron-betegségek kezelésére | |
US20050112061A1 (en) | Use of a VEGF antagonist in combination with radiation therapy | |
JP2001517208A (ja) | 損傷した細胞ペプチドプロセッシングに関連する、例えばb7−1遺伝子で形質転換したrma−s細胞上に発現される抗原またはエピトープの治療的応用 | |
WO2018212358A1 (ja) | 脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物 | |
JP5470558B2 (ja) | 脈絡膜新生血管のワクチン療法 | |
CN102217980A (zh) | 一种恒河猴脉络膜血管新生模型的制备方法 | |
FR3042121A1 (fr) | Composition anti-tumorale | |
WO2020160409A1 (en) | Methods of treating cancer using a combination of tumor membrane vesicles and metformin | |
Vishwanathan et al. | NEUROFIBROMATOSIS: A CAUSE OF CONCERN | |
KR100522526B1 (ko) | 면역 치료용 수지상 세포의 제조방법 | |
JP2021109844A (ja) | 癌治療用キット | |
US20080075705A1 (en) | Method for increasing tumor cell immunogenicity using heat shock protein | |
Queirolo et al. | Uveal melanoma | |
KR20050059031A (ko) | 체내에서 수지상세포에 종양항원을 탑재시키는 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18801526 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019518906 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018801526 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2018801526 Country of ref document: EP Effective date: 20191219 |